Shares of BB Biotech, a Swiss biotech-focused investment firm listed in the SPI, reached their highest level in three-and-a-half years on Wednesday, extending gains driven by a rally in biotech equities. The stock closed at 56.20 francs, down 0.9% on the day but up 35.7% since early June, according to the company's latest trading update.
The advance follows a second-quarter 2026 report that showed a net profit of 451 million francs, reversing losses of 21 million francs in the first quarter of 2026 and 100 million francs in the second quarter of 2025. BB Biotech also reported a total return of 17.2% for its net asset value in Q2 2026. The performance reflects gains across its portfolio holdings, including Amgen, Argenx, Vertex Pharmaceuticals and Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals recently hit its highest level since November 2024, while Amgen, Argenx and Vertex Pharmaceuticals are trading at record highs. Despite the sector-wide rally, BB Biotech noted a consolidation phase in biotechnology, emphasizing that disciplined stock selection will be critical for long-term value creation.
Analyst coverage remains limited. Julius Bär maintained a 'Hold' rating with a 48-franc price target in late July, below the current share price, while Kepler Cheuvreux set a 73-franc target with a 'Buy' recommendation in February. The company also revised its dividend policy, introducing a target payout yield of 3% to 5% to better align distributions with long-term performance. Previously, BB Biotech guaranteed a 5% dividend yield based on the average share price in December of the fiscal year.
